| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2032834 | Asian Pacific Journal of Tropical Biomedicine | 2014 | 4 Pages |
ABSTRACTObjectiveTo evaluate the effect of Manix®, the commonly used polyherbal formulation on pefloxacin pharmacokinetic parameters.MethodsMicrobiological assay was employed using clinical isolate of Escherichia coli samples from hospitalized patients.ResultsManix® altered the bioavailability parameters of pefloxacin as thus, maximal concentration (Cmax) of pefloxacin (0.91 ± 0.31) μg/mL occurred at time to reach maximal concentration (tmax) 4.0 h while in the group that received Manix® alongside pefloxacin Cmax was (0.22 ± 0.08) μg/mL at tmax 1.0 h respectively. The area under curve of pefloxacin alone was (7.83 ± 5.14) μg/h/mL while with Manix® was (2.60 ± 0.08) μg/h/mL. There was a significant difference between Cmax, tmax and area under curve between pefloxacin alone and pefloxacin after Manix® pre-treatment (P<0.05).ConclusionsThe concurrent use of Manix® and pefloxacin has been found to compromise the therapeutic effectiveness of pefloxacin which could lead to poor clinical outcomes in patients.
